However, an ADC carrying a microtubule inhibitor payload and targeting the myeloma-associated antigen BCMA has recently shown promise in heavily-pretreated multiple myeloma patients31, and thus the role of microtubule inhibitors in future of myeloma therapy is uncertain. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.